Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML
- Status
- UNKNOWN
- Phase
- PHASE1
Clinical Trials Related to AML
Related studies linked through entity extraction aliases.
Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML
- Status
- UNKNOWN
- Phase
- PHASE1
Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML
- Status
- UNKNOWN
- Phase
- PHASE1
Universal CAR-γδT Cell Injection in the AML Patients
- Status
- UNKNOWN
- Phase
- NA
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission
- Status
- RECRUITING
- Phase
- NA
Registry of Patients Having Received oNKord®
- Status
- RECRUITING
- Phase
- N/A
CC-486 and Venetoclax for Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
- Status
- TERMINATED
- Phase
- PHASE2
NK Cell Therapy for AML
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Assess an Interphase Cycle With Flotetuzumab.
- Status
- WITHDRAWN
- Phase
- PHASE2
Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis
- Status
- RECRUITING
- Phase
- PHASE2
Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML
- Status
- COMPLETED
- Phase
- PHASE2
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
- Status
- WITHDRAWN
- Phase
- N/A
Cardioprotection in AML
- Status
- RECRUITING
- Phase
- PHASE2